Option Care Health Balances CID Hit With Stable Profits

Option Care Health Inc ((OPCH)) has held its Q1 earnings call. Read on for the main highlights of the call.

Option Care Health’s latest earnings call painted a cautiously resilient picture, as strong execution in acute therapies and rising clinic utilization were overshadowed by a sharp reset in the chronic inflammatory disease portfolio. Management struck a realistic tone, acknowledging near‑term revenue pressure and a larger‑than‑expected gross profit hit, while stressing preserved profitability guidance and ample liquidity to navigate the transition.

Modest Top-Line Growth in a Challenging Quarter

Q1 2026 net revenue reached $1.4 billion, growing just over 1% year over year and falling short of prior internal expectations for stronger momentum. The limited growth reflected both the drag from chronic therapies and timing issues across certain programs, prompting a reset of full‑year revenue expectations.

Acute Portfolio Outperforms and Cushions the Blow

The company’s acute therapies continued to outperform, with revenue rising in the high single digits, well ahead of market growth. This strength generated a healthier gross profit contribution that partially offset chronic weakness and underscored Option Care Health’s competitive position in higher‑acuity services.

Profitability Metrics Hold the Line

Adjusted EBITDA came in at $105 million, down 6% from last year, while adjusted EPS held flat at $0.40, supported by a $0.02 benefit from share repurchases. Despite the revenue shortfall and margin headwinds, these results tracked internal expectations, allowing management to maintain full‑year profit guidance.

Clinic Utilization Shows Strategic Progress

Ambulatory infusion clinic visits advanced 14% year over year, highlighting the growing importance of clinic‑based care in the company’s model. Roughly 34% of nursing visits now occur in infusion suites or clinics, validating management’s strategy of shifting more care out of the home and into higher‑throughput, scalable sites.

Patient Satisfaction Remains a Competitive Strength

Patient experience metrics stayed robust, with satisfaction scores in the low 90s and Net Promoter Scores in the mid‑70s. These consistently high ratings suggest that, even amid portfolio turbulence, clinical quality and service levels remain a key differentiator that can support long‑term referral and retention trends.

Balance Sheet Flexibility Enhanced

Net leverage closed the quarter at 2.2x, leaving the company comfortably within its target range and providing room to invest. Option Care Health also expanded its revolving credit facility from $400 million to $850 million, bolstering liquidity and offering additional firepower for strategic moves or working capital needs.

Capital Allocation Stays Disciplined

The company repurchased more than $17 million of its shares in Q1, signaling confidence in long‑term value despite near‑term volatility. Management reiterated its capital priorities: fund organic growth, selectively pursue M&A in adjacencies and tuck‑ins, and undertake periodic buybacks when attractive.

Profit Guidance Intact Despite Revenue Reset

Option Care Health maintained full‑year adjusted EBITDA guidance of $480 million to $505 million and adjusted EPS of $1.82 to $1.92, even as revenue expectations were lowered. This stance implies a focus on cost discipline, mix management, and operational efficiency to protect earnings power while the chronic portfolio stabilizes.

Working Capital and Inventory Efforts Gain Traction

Early steps to optimize inventory delivered measurable improvements in the quarter, helping offset some of the revenue softness. Management expects further working capital benefits as these initiatives scale, supporting free cash flow even as growth moderates.

Revenue Miss Forces Guidance Reset

With only roughly 1% top‑line growth in Q1, the company acknowledged that revenue momentum fell short of prior expectations. Full‑year net revenue guidance was trimmed to a range of $5.675 billion to $5.775 billion, implying just over 1% growth at the midpoint and signaling a more conservative stance for 2026.

Chronic Portfolio and CID Headwinds Weigh on Growth

Chronic revenue slipped slightly year over year, as the chronic inflammatory disease portfolio reduced overall company growth by about 600 basis points in Q1. The Stelara‑related reset and broader CID disruption were called out as the primary drag on what would have otherwise been a healthier growth profile.

Gross Profit Headwind Steepens

Management now expects approximately a $55 million gross profit headwind for 2026 tied to the CID portfolio, up sharply from the earlier $25 million to $35 million estimate. This larger burden reflects a tougher therapy mix and pricing dynamics than initially modeled, forcing tighter execution elsewhere to sustain profitability.

Patient Census Reset Hits Revenue

Significant reverification activity in the chronic business more than doubled versus last year, delaying approvals into late March and disrupting normal patient flows. As some patients shifted to other providers or self‑administration, census fell more than anticipated, creating a revenue shortfall that will take time to rebuild.

Unfavorable Therapy Mix Pressures Margins

Not all biosimilars and therapies carry the same economics, and the remaining mix after the CID reset proved less favorable than planned. This shift in product‑level profitability added to revenue and margin pressure, compounding the impact of lost census in the higher‑margin segments.

Program Delays Slow Specialty Growth

Launch delays and slower ramps across several rare and orphan drug programs also muted growth that had been expected later in the year. Some specialty therapies underperformed prior assumptions, reducing an important future growth lever just as chronic volumes reset lower.

SG&A Growth Reflects Ongoing Investment

Selling, general and administrative expenses rose 4%, reflecting prior capacity builds and continued reinvestment in commercial resources. While this spending constrains near‑term margin expansion, management appears committed to preserving growth capabilities rather than cutting into strategic muscle.

Seasonal Cash Usage but Solid Cash Outlook

Operating cash flow was a modest usage of $12 million in Q1, in line with typical seasonal patterns for the business. For 2026, the company now targets at least $320 million in operating cash flow, a reset that mirrors lower revenue and cash‑based EBITDA but still signals healthy underlying cash generation.

Guidance and Outlook Emphasize Stability Over Growth

Updated 2026 guidance calls for net revenue of $5.675 billion to $5.775 billion, adjusted EBITDA of $480 million to $505 million, and adjusted EPS of $1.82 to $1.92, implying modest top‑line growth but mid‑single‑digit EBITDA and high‑single‑digit EPS expansion. Management expects Q2 to show mid‑single‑digit sequential revenue growth and high‑single‑digit sequential EBITDA growth, backed by an expanded revolver, manageable net interest expense of $50 million to $55 million, and a tax rate of 26% to 28%.

Option Care Health’s earnings call underscored a business in transition, balancing acute strength and high patient satisfaction against a meaningful chronic portfolio reset and softer revenue trajectory. For investors, the story now hinges on how quickly the company can rebuild chronic census, improve therapy mix, and convert its operational discipline and liquidity into renewed growth while preserving the profitability targets it reaffirmed for the year.